Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.09 (+0.24%) Hang Seng
17,941.78 -170.85 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
66,098.12 -126.80 (-0.19%) CMC Crypto 200
1,371.47 -46.40 (-3.27%)
REGN Jun 2024 1080.000 call
| Previous close | 3.6000 |
| Open | N/A |
| Bid | 0.0500 |
| Ask | 5.4000 |
| Strike | 1,080.00 |
| Expiry date | 2024-06-28 |
| Day's range | 3.6000 - 3.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Simply Wall St.Investors in Regeneron Pharmaceuticals (NASDAQ:REGN) have seen stellar returns of 220% over the past five years
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
ZacksRegeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion
The FDA approves label expansion of Regeneron (REGN) and Sanofi's Kevzara for the treatment of polyarticular juvenile idiopathic arthritis.
GlobeNewswireKevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Approval in patients with pJIA weighing 63kg or greater adds to Kevzara’s position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis and polymyalgia rheumatica TARRYTOWN, N.Y. and CAMBRIDGE, MA, June 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration has approved Kevzara® (sarilumab) for the treatment of patients weighing 63 kg or greater with activ
